Home > Dopamine Receptor & Dopamine Receptor & > Pergolide Mesylate

Pergolide Mesylate

甲磺酸培高利特,硫丙麦角林,LY-127809,LY127809,LY 127809

Pergolide是有抗帕金森病特性的多巴胺受体激动剂。

目录号
EY0810
EY0810
EY0810
纯度
99.58%
99.58%
99.58%
规格
5 mg
10 mg
50 mg
原价
570
780
2000
售价
570
780
2000
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Pergolide Mesylate is an antiparkinsonian agent which functions as a dopaminergic agonist.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Lemberger L, et al. Science, 1979, 205(4411), 1151-1153.
    [2] Koller, W.C., et al., The pharmacological evaluation of pergolide mesylate as a potential anti-parkinson agent. Neuropharmacology, 1980. 19(9): p. 831-7.
    [3] Schade, R., et al., Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med, 2007. 356(1): p. 29-38.

    分子式
    C20H30N2O3S2    		 分子量
    410.59    		 CAS号
    66104-23-2    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    10 mg/mL    		 Water
    80 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01066403 Schizophrenia Drug: Pergolide Heidelberg University|Stanley Medical Research Institute 2003-10-01 2010-02-09
    NCT00624741 Parkinson Disease Drug: Pergolide Valeant Pharmaceuticals International, Inc. 2012-06-20
    NCT00000269 Cocaine-Related Disorders|Substance-Related Disorders Drug: Pergolide National Institute on Drug Abuse (NIDA)|New York State Psychiatric Institute Phase 2 1995-10-01 2017-01-11
    NCT00252044 Schizotypal Personality Disorder|Other Personality Disorders Drug: Pergolide Bronx VA Medical Center 2000-10-01 2005-11-17
    NCT00197483 Schizophrenia|Negative Symptoms|Cognitive Impairments Drug: Pergolide (drug) Hamamatsu University Phase 2 2003-03-01 2005-09-13
    NCT00000248 Cocaine-Related Disorders Drug: Pergolide Medical University of South Carolina|National Institute on Drug Abuse (NIDA) Phase 3 1996-02-01 2012-09-11
    NCT00311532 Parkinson Disease Eli Lilly and Company 2006-03-01 2007-07-16
    NCT00004433 Tourette Syndrome Drug: pergolide Children's Hospital Medical Center, Cincinnati|FDA Office of Orphan Products Development 1994-12-01 2015-03-24
    NCT00000215 Cocaine-Related Disorders Drug: Pergolide National Institute on Drug Abuse (NIDA)|Columbia University Phase 2 2017-01-11
    NCT00460616 Prolactinomas Drug: Cabergoline Federico II University Phase 4 2007-01-01 2008-04-14
    NCT00260793 Parkinson's Disease Drug: Ropinirole Hydrochloride Agarwal, Pinky, M.D.|Colorado Neurology|GlaxoSmithKline Phase 3 2005-11-01 2006-02-02
    NCT00977184 Parkinson Disease Procedure: 50 HZ Repetitive TMS|Procedure: Sham rTMS National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) Phase 1|Phase 2 2009-09-01 2012-11-22
    NCT00605683 Idiopathic Parkinson's Disease Drug: Safinamide (as add-on therapy)|Drug: Safinamide (as add-on therapy)|Drug: Safinamide (as add-on therapy) Newron Phase 3 2007-11-01 2013-10-28

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：